Clinical course of Crohn’s disease in a population-based cohort in Uppsala County followed for 10 years

References

• Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997;337(15):1029–1035.
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541–1549.
   PubMed Web of Science ®Google Scholar
• Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004;350(9):876–885.
   PubMed Web of Science ®Google Scholar
• Burisch J, Kiudelis G, Kupcinskas L, et al. Natural disease course of Crohn's disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study. Gut. 2018;68(3):423–433.
   PubMed Web of Science ®Google Scholar
• Schoepfer AM, Dehlavi MA, Fournier N, et al. Diagnostic delay in Crohn's disease is associated with a complicated disease course and increased operation rate. Am J Gastroenterol. 2013;108(11):1744–1753.
   PubMed Web of Science ®Google Scholar
• Ha C, Ullman TA, Siegel CA, et al. Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population. Clin Gastroenterol Hepatol. 2012;10(9):1002–1007.
   PubMed Web of Science ®Google Scholar
• Pariente B, Mary JY, Danese S, et al. Development of the Lémann index to assess digestive tract damage in patients with Crohn's disease. Gastroenterology. 2015;148(1):52–63.e3.
   PubMed Web of Science ®Google Scholar
• Fiorino G, Bonifacio C, Allocca M, et al. Bowel damage as assessed by the Lémann index is reversible on anti-TNF therapy for Crohn's disease. J Crohns Colitis. 2015;9(8):633–639.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110(9):1324–1338.
   PubMed Web of Science ®Google Scholar
• Henriksen M, Jahnsen J, Lygren I, et al. Clinical course in Crohn's disease: results of a five-year population-based follow-up study (the IBSEN study). Scand J Gastroenterol. 2007;42(5):602–610.
   PubMed Web of Science ®Google Scholar
• Ronnblom A, Holmstrom T, Karlbom U, et al. Clinical course of Crohn's disease during the first 5 years. Results from a population-based cohort in Sweden (ICURE) diagnosed 2005–2009. Scand J Gastroenterol. 2016;52:1–6.
   PubMed Web of Science ®Google Scholar
• Sjoberg D, Holmstrom T, Larsson M, et al. Incidence and natural history of ulcerative colitis in the Uppsala Region of Sweden 2005–2009 – results from the IBD Cohort of the Uppsala Region (ICURE). J Crohns Colitis. 2013;7(9):e351–e357.
   PubMedGoogle Scholar
• Sjoberg D, Holmstrom T, Larsson M, et al. Incidence and clinical course of Crohn's disease during the first year – results from the IBD Cohort of the Uppsala Region (ICURE) of Sweden 2005–2009. J Crohns Colitis. 2014;8(3):215–222.
   PubMed Web of Science ®Google Scholar
• Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19(Suppl. A):5A–36A.
   PubMed Web of Science ®Google Scholar
• Bernell O, Lapidus A, Hellers G. Risk factors for surgery and recurrence in 907 patients with primary ileocaecal Crohn's disease. Br J Surg. 2000;87(12):1697–1701.
   PubMed Web of Science ®Google Scholar
• Solberg IC, Vatn MH, Hoie O, et al. Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol. 2007;5(12):1430–1438.
   PubMed Web of Science ®Google Scholar
• Rungoe C, Langholz E, Andersson M, et al. Changes in medical treatment and surgery rates in inflammatory bowel disease: a nationwide cohort study 1979–2011. Gut. 2014;63(10):1607–1616.
   PubMed Web of Science ®Google Scholar
• Burr NE, Lord R, Hull MA, et al. Decreasing risk of first and subsequent surgeries in patients with Crohn's disease in England from 1994 through 2013. Clin Gastroenterol Hepatol. 2019;17(10):2042–2049.e4.
   PubMed Web of Science ®Google Scholar
• Shinagawa T, Hata K, Ikeuchi H, et al. Rate of reoperation decreased significantly after year 2002 in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2020;18(4):898–907.e5.
   PubMed Web of Science ®Google Scholar
• Kalman TD, Everhov AH, Nordenvall C, et al. Decrease in primary but not in secondary abdominal surgery for Crohn's disease: nationwide cohort study, 1990–2014. Br J Surg. 2020. DOI:10.1002/bjs.11659
   Google Scholar
• To N, Gracie DJ, Ford AC. Systematic review with meta-analysis: the adverse effects of tobacco smoking on the natural history of Crohn's disease. Aliment Pharmacol Ther. 2016;43(5):549–561.
   PubMed Web of Science ®Google Scholar
• Rodu B, Cole P. The burden of mortality from smoking: comparing Sweden with other countries in the European Union. Eur J Epidemiol. 2003;19(2):129–131.
   Web of Science ®Google Scholar
• Bergstrom J. Smoking rate and periodontal disease prevalence: 40-year trends in Sweden 1970-2010. J Clin Periodontol. 2014;41(10):952–957.
   PubMed Web of Science ®Google Scholar
• Wolff BG, Beart RW Jr., Frydenberg HB, et al. The importance of disease-free margins in resections for Crohn's disease. Dis Colon Rectum. 1983;26(4):239–243.
   PubMed Web of Science ®Google Scholar
• Olaison G, Smedh K, Sjodahl R. Natural course of Crohn's disease after ileocolic resection: endoscopically visualised ileal ulcers preceding symptoms. Gut. 1992;33(3):331–335.
   PubMed Web of Science ®Google Scholar
• Raab Y, Bergstrom R, Ejerblad S, et al. Factors influencing recurrence in Crohn's disease. An analysis of a consecutive series of 353 patients treated with primary surgery. Dis Colon Rectum. 1996;39(8):918–925.
   PubMed Web of Science ®Google Scholar
• Adamina M, Bonovas S, Raine T, et al. ECCO guidelines on therapeutics in Crohn's disease: surgical treatment. J Crohns Colitis. 2020;14(2):155–168.
   PubMed Web of Science ®Google Scholar
• Lapidus A, Bernell O, Hellers G, et al. Incidence of Crohn's disease in Stockholm County 1955–1989. Gut. 1997;41(4):480–486.
   PubMed Web of Science ®Google Scholar
• Davies M, Dodd S, Coultate M, et al. From Paris to Montreal: disease regression is common during long term follow-up of paediatric Crohn's disease. Scand J Gastroenterol. 2020;55(2):148–153.
   PubMed Web of Science ®Google Scholar
• Torres J, Bonovas S, Doherty G, et al. ECCO guidelines on therapeutics in Crohn's disease: medical treatment. J Crohns Colitis. 2020;14(1):4–22.
   PubMed Web of Science ®Google Scholar
• Hart A, Ng SC, Watkins J, et al. The use of 5-aminosalicylates in Crohn's disease: a retrospective study using the UK Clinical Practice Research Datalink. Ann Gastroenterol. 2020;33(5):500–507.
   PubMed Web of Science ®Google Scholar
• Schoepfer AM, Bortolotti M, Pittet V, et al. The gap between scientific evidence and clinical practice: 5-aminosalicylates are frequently used for the treatment of Crohn's disease. Aliment Pharmacol Ther. 2014;40(8):930–937.
   PubMed Web of Science ®Google Scholar
• Duricova D, Pedersen N, Elkjaer M, et al. 5-Aminosalicylic acid dependency in Crohn's disease: a Danish Crohn Colitis Database study. J Crohns Colitis. 2010;4(5):575–581.
   PubMed Web of Science ®Google Scholar
• Gordon M, Naidoo K, Thomas AG, et al. Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn's disease. Cochrane Database Syst Rev. 2011;(1):CD008414.
   Google Scholar
• Stange EF. Review article: the effect of aminosalicylates and immunomodulation on cancer risk in inflammatory bowel disease. Aliment Pharmacol Ther. 2006;24(Suppl. 3):64–67.
   PubMedGoogle Scholar
• Elriz K, Carrat F, Carbonnel F, et al. Incidence, presentation, and prognosis of small bowel adenocarcinoma in patients with small bowel Crohn's disease: a prospective observational study. Inflamm Bowel Dis. 2013;19(9):1823–1826.
   PubMed Web of Science ®Google Scholar
• Olen O, Askling J, Sachs MC, et al. Increased mortality of patients with childhood-onset inflammatory bowel diseases, compared with the general population. Gastroenterology. 2019;156(3):614–622.
   PubMed Web of Science ®Google Scholar
• Olen O, Askling J, Sachs MC, et al. Mortality in adult-onset and elderly-onset IBD: a nationwide register-based cohort study 1964–2014. Gut. 2020;69(3):453–461.
   PubMed Web of Science ®Google Scholar
• Vester-Andersen MK, Prosberg MV, Jess T, et al. Disease course and surgery rates in inflammatory bowel disease: a population-based, 7-year follow-up study in the era of immunomodulating therapy. Am J Gastroenterol. 2014;109(5):705–714.
   PubMed Web of Science ®Google Scholar